News Update

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial

News Update
  ()
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. read more >

Preclinical COVID-19 Vaccine Data 'Encouraging'

Research Report
  ()
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. read more >

Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'

Research Report
  ()
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. read more >
News Update

Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study

News Update
  ()
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. read more >

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

  ()
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. read more >

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Research Report
  ()
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. read more >

Analyst: G1 Minimizes the Carnage of Chemotherapy

Research Report
  ()
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. read more >
News Update

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval

News Update
  ()
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. read more >

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine

  ()
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. read more >

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

Research Report
  ()
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. read more >

Expert Investing Ideas

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


"I'm excited about the new team Sproutly is bringing on."

–Jimmy Mengel, Marijuana Minifesto


"VIV signed a partnership with CSA Animal Nutrition."

–Alex Koyfman, Penny Stock Millionaire


"We are initiating coverage on PMN with an Outperform rating."

–Cosme Ordonez, Noble Capital Markets


"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

  ()
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. read more >
News Update

Telemedicine Firm to Acquire Majority Interest in Ontario Clinic

News Update
  ()
With this transaction, CloudMD Software & Services expands its size and reach. read more >

Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX

  ()
Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. read more >

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

  ()
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. read more >